Abstract

Non-uniform shortening of the action potential duration (APD90) in different myocardial regions upon heart rate acceleration can set abnormal repolarization gradients and promote arrhythmia. This study examined whether spatial heterogeneities in APD90 restitution can be amplified by drugs with clinically proved proarrhythmic potential (dofetilide, quinidine, procainamide, and flecainide) and, if so, whether these effects can translate to the appropriate changes of the ECG metrics of ventricular repolarization, such as JT intervals. In isolated, perfused guinea-pig heart preparations, monophasic action potentials and volume-conducted ECG were recorded at progressively increased pacing rates. The APD90 measured at distinct ventricular sites, as well as the JTpeak and JTend values were plotted as a function of preceding diastolic interval, and the maximum slopes of the restitution curves were determined at baseline and upon drug administration. Dofetilide, quinidine, and procainamide reverse rate-dependently prolonged APD90 and steepened the restitution curve, with effects being greater at the endocardium than epicardium, and in the right ventricular (RV) vs. the left ventricular (LV) chamber. The restitution slope was increased to a greater extent for the JTend vs. the JTpeak interval. In contrast, flecainide reduced the APD90 restitution slope at LV epicardium without producing effect at LV endocardium and RV epicardium, and reduced the JTpeak restitution slope without changing the JTend restitution. Nevertheless, with all agents, these effects translated to the amplified epicardial-to-endocardial and the LV-to-RV non-uniformities in APD90 restitution, paralleled by the increased JTend vs. JTpeak difference in the restitution slope. In summary, these findings suggest that arrhythmic drug profiles are partly attributable to the accentuated regional heterogeneities in APD90 restitution, which can be indirectly determined through ECG assessments of the JTend vs. JTpeak dynamics at variable pacing rates.

Highlights

  • In susceptible patients, antiarrhythmic drug therapies can paradoxically precipitate malignant ventricular tachyarrhythmia, torsade de pointes, thereby increasing mortality rates [1]

  • Over a range of variable diastolic intervals, action potential duration was found to be 5–10 ms shorter at left ventricular (LV) epicardium compared to the corresponding LV endocardial or right ventricular (RV) epicardial APD90 values (Fig 1, panel D)

  • A decrease in LV pacing cycle length from 550 ms to 168 ±2 ms provoked an exponential reduction of both ventricular APD90 and JT intervals, whereby the steepness of the electrical restitution curves was progressively increasing upon a reduction of the diastolic interval (Fig 1, panels E and G)

Read more

Summary

Introduction

Antiarrhythmic drug therapies can paradoxically precipitate malignant ventricular tachyarrhythmia, torsade de pointes, thereby increasing mortality rates [1]. The DIAMOND clinical trial has raised serious concerns regarding torsadogenic effects produced by dofetilide, class III antiarrhythmic agent, in patients with congestive heart failure [2]. In the CAST trial, an increase in sudden arrhythmic death was observed upon administration of flecainide, class Ic Na+ channel blocker, in patients with healed myocardial infarction [3]. Steep electrical restitution precipitates beat-to-beat oscillations in APD (electrical alternans) during tachycardia, whereas non-uniform APD shortening at distinct myocardial regions sets abnormal spatial repolarization gradients; both mechanisms, can facilitate localized conduction block leading to the wavebreak and ventricular fibrillation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call